Formulation of controlled-release capsules of biopharmaceutical classification system i drugs using niacin as a model

AAPS PharmSciTech

Volumn 11, Issue 4, 2010, Pages 1650-1661

  Chuong, Monica C ^a   Palugan, Luca ^a,b   Su, Tiffany M ^a   Busano, Claudelle ^a   Lee, Ronald ^a   Di Pretoro, Giustino ^b   Shah, Anee ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

controlled release; flowability; in vitro release; innovative formulation; niacin; particle size analysis; pellets; Raman image

Indexed keywords

NICOTINIC ACID;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG CAPSULE; DRUG FORMULATION; PRIORITY JOURNAL; WATER ABSORPTION;

CAPSULES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HYPOLIPIDEMIC AGENTS; MODELS, CHEMICAL; NIACIN; NONPRESCRIPTION DRUGS; RHEOLOGY; SOLUBILITY;

EID: 78651494540     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9543-4     Document Type: Article

References (19)

1. Sanborn KD. Physician Desk Reference, 62th ed. SloNiacin Tablet, Niaspan ER Tablet, Advicor Tablet. Montvale New Jersey: Thomson, 2008. p. 318, 1759, 1768, 3279
2. R Bamba AM Scanu 2008 "Niacin and Lipoprotein(a): Facts, Uncertainties, and Clinical Considerations." Am J Cardiol 101 8A 44B 47B 18375241
3. Dale MM, Moore PK, Rang HP, Ritter JM. Pharmacology. Scotland: Elsevier Science Limited; 2003. p. 309-13.
4. Budavari S. The Merck index: An encyclopedia of chemicals, drugs and biologicals. New Jersey: Whitehouse Station: Merck & Co., Inc; 2001. p. 6552.
5. Lemke TL, Williams DA, Roche VF, Zito SW. Foye's principles of medicinal chemistry. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1349.
6. ® Evaluations-Niacin". New Hersey: Thomson Healthcare, 2008. < http://www.thomsonhc.com/hcs/librarian/ ND-T/HCS/ND-CPR/SearchByCategory/ND-PR/Drugs/CS/532650/DUPLICATIONSHIELDSYNC/ 7BBE60/ND-PG/PRIH/ND-B/HCS/SBK/1/ND-P/Drugs/PFPUI/b8Y1pS2rM9KA5/PFActionId/hcs. common.RetrieveDocumentCommon/DocId/1278/ContentSetId/31/SearchTerm/niacin >.
7. M Davidson 2008 Niacin use and cutaneous flushing: mechanisms and strategies for prevention Am J Cardiol 101 8A 14B 19B 1:CAS:528: DC%2BD1cXlslWgsb0%3D 10.1016/j.amjcard.2008.02.028 18375236
8. MC Chuong R Lee V Saxena L Palugan 2009 Examining whether USP disintegration apparatus with a disk is superior to USP dissolution apparatus in predicting drug release during simulated fed state Dissolution Technologies 16 1 25 32 1:CAS:528:DC%2BD1MXksVWjsr0%3D
9. US P32/NF27. Chapter 711: Dissolution, Chapter 776: Optical Microscopy, Chapter 786: Particle Size Distribution, Chapter 1174: Powder Flow, and Niacin in USF Monograph. Rockville MD: Convention, Inc.; 2009. p. 263, 302, 307, 688 and 3077.
10. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Washington DC: American Pharmaceutical Association and Pharmaceutical Press; 2009. p. 111, 327, 517, 772 and 779.
11. Chuong MC and Palugan L. Innovative Sustained and Modified Release Niacin Tablets: Formulation and Drug Release Patterns. Massachusetts College of Pharmacy and Health Sciences, Faculty Development Grant Report; 2008
12. http://www.labrecyclers.com/product.html?InventoryID=1156
13. Randall CS. Chapter 6: Particle Size Distribution. In: Physical Characterization of Pharmaceutical Solids. New York: Marcel Dekker, Inc.; 1995. p. 158 and 170.
14. vwr catalog; 2008. p. 1748.
15. Dressman JJ, Kramer J. Pharmaceutical dissolution testing. New York: Informa Healthcare USA Inc.; 2005. p. 335-6.
16. www.usp.org
17. Zar JH. Biostatistical analysis. Upper Saddle River: Prentice Hall; 1999. p. 80-1.
18. www.gattefossecanada.ca/fr/products/pharmaceutical/sustained-release. shtml#compritol
19. Cha J, Ranweiler JS, Lane PA. Stability Study. In: Ahuja S, Scypinski S, editors. Handbook of modern pharmaceutical analysis. San Diego: Academic; 2001. p. 445-83.